Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas. (11th May 2019)

• Record Type: Journal Article
• Authors: Gallardo, Miguel; Malaney, Prerna; Aitken, Marisa J L; Zhang, Xiaorui; Link, Todd M; Shah, Vrutant; Alybayev, Sanzhar; Wu, Meng-Han; Pageon, Laura R; Ma, Huaxian; Jacamo, Rodrigo; Yu, Li; Xu-Monette, Zijun Y; Steinman, Haley; Lee, Hun Ju; Sarbassov, Dos; Rapado, Inmaculada; Barton, Michelle C; Martinez-Lopez, Joaquin; Bueso-Ramos, Carlos; Young, Ken H; Post, Sean M
• Is Part Of: Journal of the National Cancer Institute. Volume 112:Number 1(2020)
• Page Start: 95
• Page End: 106
• Publication Date: 2019-05-11
• Subjects: Cancer -- Periodicals; Cancer -- Research -- Periodicals; 616.994
• DOI: 10.1093/jnci/djz078
• Languages: English
• ISSNs: 0027-8874

Abstract

Abstract: Background: Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is an RNA-binding protein that is aberrantly expressed in cancers. We and others have previously shown that reduced hnRNP K expression downmodulates tumor-suppressive programs. However, overexpression of hnRNP K is the more commonly observed clinical phenomenon, yet its functional consequences and clinical significance remain unknown. Methods: Clinical implications of hnRNP K overexpression were examined through immunohistochemistry on samples from patients with diffuse large B-cell lymphoma who did not harbor MYC alterations (n = 75). A novel transgenic mouse model that overexpresses hnRNP K specifically in B cells was generated to directly examine the role of hnRNP K overexpression in mice (three transgenic lines). Molecular consequences of hnRNP K overexpression were determined through proteomics, formaldehyde-RNA-immunoprecipitation sequencing, and biochemical assays. Therapeutic response to BET-bromodomain inhibition in the context of hnRNP K overexpression was evaluated in vitro and in vivo (n = 3 per group). All statistical tests were two-sided. Results: hnRNP K is overexpressed in diffuse large B-cell lymphoma patients without MYC genomic alterations. This overexpression is associated with dismal overall survival and progression-free survival ( P < .001). Overexpression of hnRNP K in transgenic mice resulted in the development of lymphomas and reduced survival ( P < .001 for all transgenic lines; Line 171[n = 30]: hazard ratio [HR] = 64.23, 95% confidence interval [CI] = 26.1 to 158.0; Line 173 [n = 31]: HR = 25.27, 95% CI = 10.3 to 62.1; Line 177 [n = 25]: HR = 119.5, 95% CI = 42.7 to 334.2, compared with wild-type mice). Clinical samples, mouse models, global screening assays, and biochemical studies revealed that hnRNP K's oncogenic potential stems from its ability to posttranscriptionally and translationally regulate MYC . Consequently, Hnrnpk overexpression renders cells sensitive to BET-bromodomain-inhibition in both in vitro and transplantation models, which represents a strategy for mitigating hnRNP K-mediated c-Myc activation in patients. Conclusion: Our findings indicate that hnRNP K is a bona fide oncogene when overexpressed and represents a novel mechanism for c-Myc activation in the absence of MYC lesions.